New combo aims to shrink tough colon cancers before surgery
NCT ID NCT06890624
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether a stronger chemotherapy cocktail (cmFOLFOXIRI) plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemotherapy (mFOLFOX6) when given before surgery for locally advanced colon cancer. About 138 patients with high-risk stage II or III colon cancer will be randomly assigned to one of the two treatments. The main goal is to see if the new combo leads to a higher rate of complete tumor disappearance (pathologic complete response) at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cmFOLFOXIRI plus PD-1 inhibitor (a combination of chemotherapy drugs and an immunotherapy drug)
- What this could lead to
- If successful, this could lead to a more effective pre-surgery treatment for advanced colon cancer, potentially increasing the chance of complete tumor removal and reducing recurrence.
- What could go wrong
- This is an early phase II trial with only 138 participants, so results may not apply to all patients. The combination therapy may cause more side effects than standard chemotherapy, and it is not yet proven to improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER (STAGE II & III) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.